Malta - English - Medicines Authority

mercury pharmaceuticals (ireland) limited 4045 kingswood road, city west business park, co, dublin, ireland - neostigmine metilsulfate - solution for injection - neostigmine metilsulfate 2.5 mg/ml - other nervous system drugs

Ireland - English - HPRA (Health Products Regulatory Authority)

mercury pharmaceuticals (ireland) ltd - neostigmine metilsulfate - solution for injection - 2.5 milligram(s)/millilitre - anticholinesterases; neostigmine

Panama - English - Ministerio de Salud (Dirección Nacional de Farmacia Y Drogas)

laboratorio sanderson s.a. - neostigmina metilsulfato - neostigmina metilsulfato....0.5 mg

Panama - English - Ministerio de Salud (Dirección Nacional de Farmacia Y Drogas)

vitalis s.a.c.i. - neostigmina metilsulfato - neostigmina metilsulfato....0.5 mg

Ireland - English - HPRA (Health Products Regulatory Authority)

mercurypharm ltd - glycopyrronium bromide; neostigmine metilsulfate - solution for injection - 0.5mg /2.5 milligram(s)/millilitre - anticholinesterases; neostigmine, combinations

New Zealand - English - Medsafe (Medicines Safety Authority)

astrazeneca limited - neostigmine metilsulfate 0.5 mg/ml - solution for injection - 0.5 mg/ml - active: neostigmine metilsulfate 0.5 mg/ml excipient: dibasic sodium phosphate dodecahydrate monobasic sodium phosphate dihydrate sodium chloride water for injection

New Zealand - English - Medsafe (Medicines Safety Authority)

juno pharmaceuticals nz limited - neostigmine metilsulfate 2.5 mg/ml - solution for injection - 2.5 mg/ml - active: neostigmine metilsulfate 2.5 mg/ml excipient: dibasic sodium phosphate dodecahydrate monobasic sodium phosphate dihydrate sodium chloride water for injection - · reversal of the effects of nondepolarising neuromuscular blocking agents (e.g. tubocurarine, pancuronium etc.).

New Zealand - English - Medsafe (Medicines Safety Authority)

max health limited - neostigmine metilsulfate 2.5 mg/ml - solution for injection - 2.5 mg/ml - active: neostigmine metilsulfate 2.5 mg/ml excipient: nitrogen sodium chloride water for injection - · propylaxis and treatment of post-operative intestinal atony and urinary retention.

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

hameln pharma ltd - neostigmine metilsulfate - solution for injection - 2.5mg/1ml

United States - English - NLM (National Library of Medicine)

general injectables and vaccines, inc - neostigmine methylsulfate (unii: 98imh7m386) (neostigmine - unii:3982twq96g) - neostigmine methylsulfate 1 mg in 1 ml - neostigmine methylsulfate injection, a cholinesterase inhibitor, is indicated for reversal of the effects of nondepolarizing neuromuscular blocking agents (nmba) after surgery.  neostigmine is contraindicated in patients with: - known hypersensitivity to neostigmine methylsulfate (known hypersensitivity reactions have included urticaria, angioedema, erythema multiforme, generalized rash, facial swelling, peripheral edema, pyrexia, flushing, hypotension, bronchospasm, bradycardia and anaphylaxis).  - peritonitis or mechanical obstruction of the urinary or intestinal tracts. pregnancy risk summary there are no adequate or well-controlled studies of neostigmine methylsulfate injection in pregnant women.  it is not known whether neostigmine methylsulfate injection can cause fetal harm when administered to a pregnant woman or can affect reproductive capacity.  the incidence of malformations in human pregnancies has not been established for neostigmine as the data are limited.  all pregnancies, regardless of drug e